IP Library Granted Patent US 11,198,716
Granted Patent B2
US 11,198,716 · App. 15/814,723 · Granted Dec 14, 2021

Recombinant proteins and their therapeutic uses

Inventors: Keith Alan Charlton (Aberdeen, GB); Erik D'Hondt (Bazel, BE)
Assignee: IN3BIO LTD.
C07K14/485A61K39/0005A61K39/0011C07K14/28C07K14/475C07K14/4748C07K14/4753C07K14/48C07K14/495C07K14/50C07K14/65C07K14/71C12N9/12C12N9/6424A61K2039/645A61K2039/70C07K2319/40Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,198,716
App. No.
15/814,723
Granted
Dec 14, 2021
Kind
B2
Abstract

A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.

Claims (24)

1. A recombinant protein, comprising:

an immunogenic polypeptide;

a peptide spacer selected from the group consisting of SSGGG (SEQ. ID NO: 4), GGSGG (SEQ. ID NO: 3), SSGGGSGG (SEQ. ID NO: 8), SSGGGGSGGG (SEQ. ID NO: 9), TSGGGSG (SEQ. ID NO: 10), TSGGGGSGG (SEQ. ID NO: 11), SSGGGSGGSSG (SEQ. ID NO: 12), GGSGGTSGGGSG (SEQ. ID NO: 13), SGGTSGGGGSGG (SEQ. ID NO: 14), GGSGGTSGGGGSGG (SEQ. ID NO: 15), SSGGGGSGGGSSG (SEQ. ID NO: 16), SSGGGSGGSSGGG (SEQ. ID NO: 17), SSGGGGSGGGSSGGG (SEQ. ID NO: 18), and GGSGGTRPSTAATS (SEQ. ID NO: 19), and

a polypeptide including a neutralizing domain of a self-protein growth factor,

wherein said immunogenic polypeptide is separated from said polypeptide by said peptide spacer.

2. The recombinant protein according to claim 1 , wherein said immunogenic polypeptide includes a cholera toxin B (CT-B) protein.

3. The recombinant protein according to claim 1 , wherein said self-protein growth factor includes an epidermal growth factor (EGF).

4. The recombinant protein according to claim 1 , wherein said neutralizing domain includes a B-loop of an epidermal growth factor (EGF).

5. The recombinant protein according to claim 1 , wherein said self-protein growth factor includes a full length or part thereof of one or more growth factors selected from the group consisting of IGF-1, IGF-2, FGF1, FGF2, TGF-α, TGF-β, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF, NGF, EGF, HGF, BMP's, and IL's 1-6.

6. The recombinant protein according to claim 1 , wherein said polypeptide includes a full length or neutralizing domain of at least two different growth factors.

7. The recombinant protein according claim 1 , wherein said polypeptide includes a full length or neutralizing domain of one or more growth factors as a single domain or as two or more tandem repeats.

8. A process of preparing a multivalent molecule comprising:

assembling multimers from one or more monomeric sub-units to form a synthetic protein including one or more growth factors or parts thereof, wherein the monomeric sub-units are the recombinant protein of claim 1 .

9. The recombinant protein according to claim 1 , wherein said peptide spacer is configured to reduce steric hindrance between said immunogenic polypeptide and said polypeptide.

10. The recombinant protein according to claim 1 , wherein said immunogenic polypeptide includes a cholera toxin B (CT-B) protein.

11. The recombinant protein according to claim 1 , wherein said growth factor is an epidermal growth factor (EGF).

12. An immunogenic composition, comprising:

an immunogenic polypeptide;

a peptide spacer selected from the group consisting of SSGGG (SEQ. ID NO: 4), GGSGG (SEQ. ID NO: 3), SSGGGSGG (SEQ. ID NO: 8), SSGGGGSGGG (SEQ. ID NO: 9), TSGGGSG (SEQ. ID NO: 10), TSGGGGSGG (SEQ. ID NO: 11), SSGGGSGGSSG (SEQ. ID NO: 12), GGSGGTSGGGSG (SEQ. ID NO: 13), SGGTSGGGGSGG (SEQ. ID NO: 14), GGSGGTSGGGGSGG (SEQ. ID NO: 15), SSGGGGSGGGSSG (SEQ. ID NO: 16), SSGGGSGGSSGGG (SEQ. ID NO: 17), SSGGGGSGGGSSGGG (SEQ. ID NO: 18), and GGSGGTRPSTAATS (SEQ. ID NO: 19); and

a polypeptide including a neutralizing domain of a growth factor,

wherein said immunogenic polypeptide is separated from said polypeptide by said peptide spacer.

13. The immunogenic composition of claim 12 , wherein said growth factor is a human self-protein growth factor.

14. The immunogenic composition of claim 12 , wherein said growth factor includes a full length or part thereof of one or more growth factors selected from the group consisting of IGF-1, IGF-2, FGF1, FGF2, TGF-α, TGF-β, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF, NGF, EGF, HGF, BMP's, and IL's 1-6.

15. The immunogenic composition of claim 14 , wherein said growth factor includes a full length or part thereof of IGF-1, IGF-2, EGF, and combinations thereof.

Assignments (3)
SECURITY INTEREST Recorded Feb 4, 2026
From: IN3BIO LTD.
To: WITHERS BERGMAN LLP
Reel/Frame 074607/0289 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2021
From: CHARLTON, KEITH ALAN; D'HONDT, ERIK
To: BIOVEN 3 LIMITED
Reel/Frame 057267/0275 →
CHANGE OF NAME Recorded Aug 24, 2021
From: BIOVEN 3 LIMITED
To: IN3BIO LTD.
Reel/Frame 057267/0317 →
Continuity (5)
Continuation 14996553 · Jan 15, 2016
Continuation 13813844
Provisional Application 61654401 · Jun 1, 2012
Provisional Application 61563128 · Nov 23, 2011
Related Publication 20180162917A1 · Jun 14, 2018
Cited By (1)
US 12,570,708